Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT03832660

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03832660
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany, Italy, Serbia, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03832660. Randomized; no masking; primary purpose treatment. Start 2019-05-03 (actual); primary completion 2022-05-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
Acronym
SILICOFCM
Condition
Hypertrophic Cardiomyopathy
Intervention (Behavioral)
Lifestyle
Intervention (Drug)
Sacubitril/Valsartan
Lead sponsor
Newcastle University (class: other)
Collaborator
Azienda Ospedaliero-Universitaria Careggi (class: other)
Collaborator
University Hospital Regensburg (class: other)
Collaborator
Institute of Cardiovascular Diseases, Vojvodina (class: other)
Collaborator
University of Belgrade (class: other)

Record details

Record id
cardio:ct-nct03832660
Content hash
2cf336780071b948bf774c63292749a2004f4f7524308306abee972197c59e5d